New asthma drug candidate enters first human safety tests
NCT ID NCT06637371
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called AMG 691 in 21 healthy volunteers and people with mild-to-moderate asthma. The main goal is to see if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as an injection under the skin. This study does not aim to treat asthma but to gather essential safety data before larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 691 (an experimental drug given as an injection under the skin)
What this could lead to
If this early study shows the drug is safe, it could lead to larger trials testing whether AMG 691 helps control asthma symptoms.
What could go wrong
This is a very small, early-phase trial focused on safety, not on whether the drug works for asthma. Many drugs that appear safe in Phase 1 fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Algemeen Ziekenhuis Sint Maarten-Emmaus vzw
Mechelen, 2800, Belgium
-
Allergy Asthma and Clinical Research Center
Oklahoma City, Oklahoma, 73120, United States
-
Brigham and Womens Hospital
Boston, Massachusetts, 02115, United States
-
Chelsea and Westminster Hospital
London, SW10 9NH, United Kingdom
-
Chesapeake Clinical Research Inc
White Marsh, Maryland, 21162, United States
-
ClinCept, LLC
Columbus, Georgia, 31904, United States
-
Clinical Medical and Analytical eXellence CMAX
Adelaide, South Australia, 5000, Australia
-
Destiny Research Center
Palmetto Bay, Florida, 33157, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Mayflower Clinical
South Dartmouth, Massachusetts, 02747, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Monroe Biomedical Research
Monroe, North Carolina, 28112, United States
-
Monroe Biomedical Research
North Charleston, South Carolina, 29406, United States
-
North Carolina Clinical Research
Raleigh, North Carolina, 27607, United States
-
Orange County Research Center
Lake Forest, California, 92630, United States
-
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, 55114, United States
-
The Medicines Evaluation Unit
Manchester, M23 9QZ, United Kingdom
-
Translational Clinical Research LLC
Aventura, Florida, 33180, United States
-
University of North Carolina Clinical and Translational Research Center
Chapel Hill, North Carolina, 27599, United States
-
VPD Heart and Lung Research Institute
Cambridge, CB2 0AY, United Kingdom
-
Winchester District Memorial Hospital
Winchester, Ontario, K0C 2K0, Canada